Search Resources (English): Health Canada, Women and Health Protection (WHP)

9 results

Results

Transparency and the drug approval process at Health Canada: policy brief  
http://www.whp-apsf.ca/en/documents/trans_policy.html

Argues that the lack of transparency in the drug approval process can lead to inappropriate, unnecessary and sometimes dangerous drug use, and it impedes the development of knowledge and appropriate decision-making.

 (See Details)
Published: 2006
Transparency and the drug approval process at Health Canada  
http://www.whp-apsf.ca/en/documents/transparency.html
Argues that the federal government is protecting drug companies instead of the public by keeping information about the drug approval process secret. Examines the impact of this on women's health. (See Details)
Published: 2005
How safe are our medicines? Monitoring the risks of drugs after they are approved for marketing  
http://www.whp-apsf.ca/en/documents/how_safe.html
Discusses the drug approval process in Canada, post-approval drug surveillance, adverse drug reactions, and notification of those at risk of harm. Recommends measures to ensure drug safety for Canadian women and their families. (See Details)
Published: 2000
Women and adverse drug reactions: reporting in the Canadian context  
http://www.whp-apsf.ca/pdf/fullerReport.pdf
Provides an overview of how Canada's program for reporting Adverse Drug Reactions (ADRs) supports-or doesn't support-an effective women's health strategy related to prescription drug use. (See Details)
Published: 2002, 2003
Reporting harm caused by medicines  
http://www.whp-apsf.ca/en/documents/adrReport.html
Discusses why women should report all cases of known or suspected harm from prescription drugs and medicines. Provides contact information for consumers who wish to file a report. (See Details)
Published: 2005
Post-market surveillance of therapeutic drugs in Canada  
http://www.whp-apsf.ca/en/documents/adrBackground.html
Discusses the importance of an effective post-market surveillance system of therapeutic drugs. Lists problems with the current system, and argues that improvements will only occur when there is greater consumer involvement. (See Details)
Published: 2005
Same tune, different lyrics: the Vioxx story  
http://www.cwhn.ca/node/39500
Illustrates the flaws in the Canadian drug approval and drug regulatory processes, using the current Vioxx scandal as example. (See Details)
Published: 2005
Breast implants public forum: concerns about Health Canada's process  
http://www.whp-apsf.ca/en/documents/concerns.html

Ann Rochon Ford, coordinator of Women and Health Protection composed a letter of concerns around the process of Health Canada's regulation hearings for breast implant use in Canada.  The link includes the reply from Health Canada and further concerns raised by Rochon Ford.

 (See Details)
Published: 2005
What should public consultation look like?  
http://www.whp-apsf.ca/en/documents/pub-consult.html

The thesis of this article is that the Canadian tradition of secrecy around the approval of drugs and devices, coupled with inadequate post-marketing surveillance, has harmed Canadian women and their families. Mains states that proposed changes to the legislative framework must ensure greater transparency and accountability to the approval process as well as enforcement of more stringent conflict of interest guidelines. This peice includes a list of recommendations.

 (See Details)
Published: July 2000